Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results KIRKLAND, Wash., September 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance are likely to drive short‑term buying pressure, though elevated expenses and net loss temper the outlook.
Market read
First‑report earnings and guidance lift provide fresh material for traders; the news is material for KMTS shareholders and sector peers.
What to watch
Cash burn remains high and operating expenses rose sharply, which could pressure margins.
Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial Results
Revenue increased 60% and gross margin expanded to 56.5%, while FY27 revenue guidance increased to $141 million. However, GAAP net loss widened to $44.1 million, adjusted EBITDA loss widened to $24.0 million, and net cash used in operating activities increased to $32.3 million.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| RevenueGAAP | $30.97M | – | 60% |
| Cost of revenueGAAP | $13.47M | – | – |
| Gross profitGAAP | $17.50M | – | – |
| Gross marginGAAP | 56.5% | – | – |
| Research and development expenseGAAP | $6.80M | – | – |
| Selling, general and administrative expenseGAAP | $48.36M | – | – |
| Total operating expensesGAAP | $55.16M | – | – |
| Adjusted operating expensesnon-GAAP | $44.21M | – | – |
| Loss from operationsGAAP | −$37.66M | – | – |
| Interest expenseGAAP | $1.93M | – | – |
| Interest incomeGAAP | −$2.13M | – | – |
| Other expense (income), netGAAP | $272K | – | – |
| Loss on extinguishment of debtGAAP | $6.30M | – | – |
| Net loss before provision for income taxesGAAP | −$44.04M | – | – |
| Provision for income taxesGAAP | $50K | – | – |
| Net loss attributable to common shareholders, basic and dilutedGAAP | −$44.09M | – | – |
| Net loss per share attributable to common shareholders, basic and dilutedGAAP | $(0.75) | – | – |
| Weighted-average common shares outstanding, basic and dilutedGAAP | 58,566,467 | – | – |
| Comprehensive lossGAAP | −$44.34M | – | – |
| Adjusted EBITDAnon-GAAP | −$24.05M | – | – |
| Net cash used in operating activitiesGAAP | −$32.30M | – | – |
| Purchases of property and equipmentGAAP | −$8.34M | – | – |
| Net cash used in investing activitiesGAAP | −$21.35M | – | – |
| Net cash provided by (used in) financing activitiesGAAP | $22.50M | – | – |
| Net decrease in cash, cash equivalents and restricted cashGAAP | −$31.15M | – | – |
| Cash and cash equivalentsGAAP | $68.56M | – | – |
| Cash, cash equivalents, and investmentsother | $244.7M | – | – |
| Long-term debt, netGAAP | $72.50M | – | – |
FY27 outlook
- Revenue$141 million
- NoteRevenue growth of 48% compared to FY26.
- NotePrior FY27 revenue guidance was $137 million.
What drove it
- Revenue growth was driven by wearable cardioverter defibrillator market expansion, competitive share gains, new sales territories, a higher mix of in-network patients, and ongoing improvements in revenue cycle management capabilities.
- Gross-margin expansion was driven by volume leverage, a higher mix of in-network patients, and execution of planned cost improvement programs.
- The increase in adjusted operating expenses was primarily attributable to commercial expansion and accelerated investment in key R&D programs.
Concerns
- GAAP net loss was $(44,087) thousand, compared to $(25,826) thousand in the prior-year period.
- Adjusted EBITDA loss was $(24,046) thousand, compared to $(19,405) thousand in the prior-year period.
- Loss on extinguishment of debt was $6,304 thousand.
- GAAP operating expenses were $55,155 thousand, compared to $37,729 thousand in the prior-year period.
- Net cash used in operating activities was $(32,295) thousand, compared to $(26,274) thousand in the prior-year period.
What to watch
- Execution against FY27 revenue guidance of $141 million.
- Continuation of gross-margin performance following the reported 56.5% gross margin.
- Commercial-expansion and R&D spending, which management identified as drivers of higher operating expenses.
- Operating cash usage and the deployment of liquidity, including committed unused availability under the term loan agreement.
- Wearable cardioverter defibrillator market expansion, competitive share gains, in-network patient mix, and revenue cycle management improvements.
Balance sheet and cash flow
- Cash and cash equivalents were $68,558 thousand as of July 31, 2026, compared to $99,710 thousand as of April 30, 2026.
- Short-term investments were $130,353 thousand as of July 31, 2026, compared to $96,724 thousand as of April 30, 2026.
- Long-term investments were $45,791 thousand as of July 31, 2026, compared to $65,767 thousand as of April 30, 2026.
- Cash, cash equivalents, and investments totaled $244,702 thousand as of July 31, 2026.
- Kestra reported total liquidity of approximately $320 million including committed unused availability under its term loan agreement.
- Long-term debt, net was $72,495 thousand as of July 31, 2026, compared to $42,649 thousand as of April 30, 2026.
- Net cash used in operating activities was $(32,295) thousand, compared to $(26,274) thousand in the prior-year period.
- Net cash used in investing activities was $(21,352) thousand, compared to $(8,232) thousand in the prior-year period.
- Proceeds from issuance of long-term debt were $75,000 thousand and repayment of long-term debt was $(46,395) thousand.
- Net cash provided by financing activities was $22,495 thousand, compared to net cash used in financing activities of $(1,875) thousand in the prior-year period.
Analysis
Kestra reported first-quarter fiscal 2027 revenue of $30,971 thousand, up 60% from $19,371 thousand in the prior-year period. Management attributed growth to wearable cardioverter defibrillator market expansion, competitive share gains, new sales territories, a higher mix of in-network patients, and improved revenue cycle management. No reportable operating segments were disclosed in the filing.
Gross profit was $17,498 thousand versus $8,851 thousand, and gross margin expanded to 56.5% from 45.7%. The company cited volume leverage, in-network mix, and planned cost improvement programs as the reasons for the margin improvement. This margin expansion accompanied revenue growth despite cost of revenue rising to $13,473 thousand from $10,520 thousand.
The company continued to invest heavily in commercialization and development. GAAP operating expenses increased to $55,155 thousand from $37,729 thousand, including research and development expense of $6,796 thousand and selling, general and administrative expense of $48,359 thousand. Adjusted operating expenses were $44,208 thousand versus $30,284 thousand. The higher expense base, together with a $6,304 thousand loss on extinguishment of debt, contributed to a GAAP net loss of $(44,087) thousand, compared with $(25,826) thousand, while adjusted EBITDA loss widened to $(24,046) thousand from $(19,405) thousand.
Cash consumption remained material. Net cash used in operating activities was $(32,295) thousand and purchases of property and equipment were $(8,335) thousand. Cash, cash equivalents, and investments totaled $244,702 thousand as of July 31, 2026, and the company cited total liquidity of approximately $320 million including committed unused availability under its term loan agreement. Long-term debt, net was $72,495 thousand, after $75,000 thousand of debt issuance and $(46,395) thousand of debt repayment during the period.
Management increased FY27 revenue guidance to $141 million from prior FY27 revenue guidance of $137 million and stated that the new guide represents growth of 48% compared to FY26. The filing did not provide FY27 guidance for gross margin, operating expenses, tax rate, profitability, EBITDA, cash flow, or capital expenditures. The central reported trade-off is rapid revenue and gross-margin expansion against higher commercial and R&D spending, a wider reported net loss, and increased operating cash use.
Management, verbatim
Kestra delivered another strong quarter of financial performance, generating revenue growth of 60% while expanding gross margin to over 56%.
Brian Webster, President and CEO
We remain confident that our focus on innovation and commercial expansion positions Kestra to generate durable, top-tier growth for years to come.
Brian Webster, President and CEO
Our team is executing on its commitments to prescribers and their patients and we believe this will continue to drive market expansion and advance Kestra on its path to market leadership.
Brian Webster, President and CEO
Not in the filing
stated, not guessed- Prior-period outlook section was not provided; therefore, no actual-versus-prior-guidance comparison is included.
- No revenue by operating segment was disclosed.
- Non-GAAP net income or loss and non-GAAP earnings per share were not disclosed.
- Free cash flow was not disclosed.
- No guidance was provided for gross margin, operating expenses, tax rate, net income or loss, adjusted EBITDA, operating cash flow, free cash flow, capital expenditures, cash, or debt.
- No share repurchase program, repurchases, dividends, or dividend guidance was disclosed.
- Prior-quarter comparisons were not disclosed for the income statement, cash flow statement, or operating metrics.
- Percentage changes were not printed for gross profit, operating expenses, operating loss, net loss, adjusted EBITDA, or cash flow metrics.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Kestra Medical Technologies disclosed its Q1 FY2027 financials via an SEC Form 8‑K, including revenue growth, margin expansion, and an updated FY27 revenue target.
Ticker impact
Filed 8‑K reporting Q1 FY2027 results and raised FY27 revenue guidance to $141 million.
expect price to rise on the news
Revenue jumped 60% YoY and gross margin expanded, while guidance was increased, indicating strong growth momentum.
Market effects
Wearable medical device sector may see increased investor interest.
U.S. biotech/medtech investors could allocate more capital to similar firms.
Limited to niche medtech segment; no broad market effect.
Counterpoint
Higher guidance may already be priced in; execution risk could limit upside.
Key entities
- CompanyKestra Medical Technologies, Ltd.
Wearable medical device and digital healthcare firm.
